| Item Type | Name |
|
Concept
|
Consumer Product Safety
|
|
Concept
|
Safety
|
|
Concept
|
Safety Management
|
|
Concept
|
Patient Safety
|
|
Academic Article
|
Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease.
|
|
Academic Article
|
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
|
|
Academic Article
|
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
|
|
Academic Article
|
Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
|
|
Academic Article
|
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
|
|
Academic Article
|
Treatment of inflammatory bowel disease: safety and tolerability issues.
|
|
Academic Article
|
Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis.
|
|
Academic Article
|
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies.
|
|
Academic Article
|
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
|
|
Academic Article
|
Safety first: messages from Digestive Disease Week 2006.
|
|
Academic Article
|
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
|
|
Academic Article
|
Balancing drug availability and patient safety.
|
|
Academic Article
|
Indecent exposures.
|
|
Academic Article
|
Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease.
|
|
Academic Article
|
Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.
|
|
Academic Article
|
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
|
|
Academic Article
|
Balancing drug availability and patient safety.
|
|
Academic Article
|
Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin.
|
|
Academic Article
|
Review article: safety of infliximab in clinical trials.
|
|
Academic Article
|
More food for thought.
|
|
Academic Article
|
Quality indicators for inflammatory bowel disease: development of process and outcome measures.
|
|
Academic Article
|
Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
|
|
Academic Article
|
Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant crohn's disease: a phase 1 study.
|
|
Academic Article
|
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease.
|
|
Academic Article
|
Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohn's Disease: A Phase 1b/2a Study.
|
|
Academic Article
|
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
|
|
Academic Article
|
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
|
|
Academic Article
|
Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).
|
|
Academic Article
|
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
|
|
Academic Article
|
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
|
|
Academic Article
|
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
|
|
Academic Article
|
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
|
|
Academic Article
|
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
|
|
Academic Article
|
Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate).
|
|
Academic Article
|
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis.
|
|
Academic Article
|
Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease.
|
|
Academic Article
|
Efficacy and Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
|